INVO Bioscience

IINVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NAYA Biosciences, Inc. operates a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on October 14, 2024 and is headquartered in Sarasota, FL.

SARASOTA, Fla. , Aug. 4, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock.

INVO Bioscience Announces Pricing of $4.5 Million Public Offering

Company sets closing date deadline of acquisition to August 10, 2023 -- Acquisition is expected to significantly enhance total annual revenue and contribute positive net income to the company's operating results Transition to healthcare services company allows INVO to accelerate IVC volume, allowing for a greater share in total fertility cycle revenue Targeting cash flow breakeven in 2024 SARASOTA, Fla. , Aug. 3, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has extended the deadline to acquire Wisconsin Fertility Institute (WFI) to August 10, 2023.

INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder Value

Invo Bioscience (NASDAQ: INVO ) stock appears to be rocketing higher on Friday but it's actually undergoing a reverse stock split. Invo Bioscience has enacted a one-for-20 reverse stock split that went into effect this morning.

Why Is Invo Bioscience (INVO) Stock Up 2,000% Today?

SARASOTA, Fla. , July 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that it will effect a 1-for-20 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m.

INVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023

INVOcell now cleared for 5-day incubation period Supporting data reflects improved patient outcomes, similar to IVF SARASOTA, Fla. , June 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period.

INVO Receives 510(k) FDA Clearance for Expanded Use of the INVOcell Device

INVO Bioscience (NASDAQ: INVO ) stock is on the rise Monday after the company announced a public share offering on Friday. According to a Securities and Exchange Commission (SEC) filing from INVO Bioscience, certain investors may offer up to 6,241,493 shares of INVO stock.

Why Is INVO Bioscience (INVO) Stock Up 82% Today

INVO Bioscience, Inc. (NASDAQ:INVO ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Robert Blum - Lytham Partners Steve Shum - CEO Mike Campbell - Chief Operating Officer and VP of Business Development Andrea Goren - Chief Financial Officer Conference Call Participants Joanne Lee - Maxim Group Rodney Baber - Paulson Investments Operator Good day. And welcome to the INVO First Quarter 2023 Financial Results Conference Call.

INVO Bioscience, Inc. (INVO) Q1 2023 Earnings Call Transcript

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , May 15, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the quarter ended March 31, 2023 and provided a business update.

INVO Reports First Quarter 2023 Financial Results

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its first quarter 2023, for the period ended March 31, 2023, after the market close on Monday, May 15, 2023.

INVO Bioscience to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

INVO Bioscience, Inc. (NASDAQ:INVO) Q4 2022 Earnings Conference Call April 17, 2023 4:30 PM ET

INVO Bioscience, Inc. (INVO) Q4 2022 Earnings Call Transcript

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

INVO Reports Fourth Quarter and Full Year 2022 Financial Results

INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its fourth quarter and fiscal year 2022, for the period ended December 31, 2022, after the market close on Monday, April 17, 2023. The Company has scheduled a conference call that same day, Monday, April 17, 2023, at 4:30 pm ET, to review the results.

INVO Bioscience to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Monday, April 17, 2023

INVO recently announced the signing of binding agreements to acquire this top-rated clinic SARASOTA, Fla. and MADISON, Wis.

INVO Congratulates Wisconsin Fertility Institute on Being Named One of America's Best Fertility Clinics by Newsweek

SARASOTA, Fla. , March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced preliminary financial results for the fourth quarter and year ended December 31, 2022.

INVO Provides Preliminary Update on FY2022 Financial Results

SARASOTA, Fla. , March 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the closing of its previously announced registered direct offering of 3,680,000 shares of common stock (or pre-funded warrants in lieu thereof), priced at-the-market under Nasdaq rules.

INVO Bioscience Announces Closing of $3.0 Million Registered Direct Offering

INVO Bioscience announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to buy 3,680,000 shares of common stock. The post INVO Bioscience Announces Pricing of $3 Million Registered Direct Offering Priced At-The-Market appeared first on Pulse 2.0.

INVO Bioscience Announces Pricing of $3 Million Registered Direct Offering Priced At-The-Market

SARASOTA, Fla. , March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor to purchase 3,680,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market

Allarity Therapeutics

Asensus Surgical

Penny stocks under $1 to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 3 Under $0.99 To Watch Now

Accretive acquisition expected to add significant scale to INVO's operations Contributes  over $5 million in incremental annual revenue as well as positive net income Initial transaction that establishes acquisitions as 3rd key aspect of INVO's commercial strategy, in addition to building new INVO Centers and partnering with existing IVF clinics SARASOTA, Fla. and MADISON, Wis.

INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute

SARASOTA, Fla. , Jan. 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has entered an exclusive distribution agreement with Ming Mei Technology Co. Ltd ("Ming Mei") for Taiwan.

INVO Bioscience Enters Distribution Agreement for Taiwan

Shelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa-based INVO Center.

INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center

Patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOcell provides an advanced, effective and affordable infertility treatment option to help increase access to care. The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030 yet remains severely underserved with many patients unable to access affordable treatment.

First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

INVO Bioscience, Inc. (NASDAQ:INVO ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Robert Blum - Lytham Partners, IR Steven Shum - Chief Executive Officer Mike Campbell - Chief Operating Officer and VP, Business Development Andrea Goren - Chief Financial Officer Conference Call Participants John Heerdink - Vista Partners LLC Operator Good day. And welcome to the INVO Bioscience Reports on the Third Quarter 2022 Financial Results Call.

INVO Bioscience, Inc. (INVO) Q3 2022 Earnings Call Transcript

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Nov. 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

INVO Bioscience Reports Third Quarter 2022 Financial Results

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Nov. 10, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its third quarter 2022, ended September 30, 2022, after the market close on Monday, November 14, 2022.

News for INVO Bioscience Stock (INVO)